|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72.55 CNY | +4.69% |
|
+3.35% | +6.58% |
EPS & Dividend: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Dividend per Share 2 | - | - | - | 0.2 | 1 | 0.18 | 0.24 | 0.3 |
| Rate of return | - | - | - | 0.38% | 2.27% | 0.25% | 0.33% | 0.41% |
| EPS 2 | 2.31 | 2.59 | -0.78 | 0.6 | 1.04 | 1.85 | 2.405 | 2.967 |
| Distribution rate | - | - | - | 33.3% | 96.2% | 9.73% | 9.98% | 10.1% |
| Reference price 2 | 132.22 | 70.34 | 32.58 | 52.65 | 44.10 | 72.55 | 72.55 | 72.55 |
| Nbr of stocks (in thousands) | 561,540 | 561,540 | 565,653 | 590,049 | 597,089 | 595,202 | 595,202 | - |
| Announcement Date | 14/04/21 | 27/04/22 | 30/03/23 | 24/04/24 | 24/04/25 | - | - | - |
1CNY in Million2CNY
Estimates
Past dividends: Gan & Lee Pharmaceuticals.
| 10/06/2025 | Final Payment 1 CNY |
| 01/12/2024 | Interim Payment 0.5 CNY |
| 17/06/2024 | Annual 0.2 CNY |
| 19/06/2022 | Annual 0.3 CNY |
| 20/05/2021 | Annual 0.4 CNY |
| 19/08/2020 | Annual 0.5 CNY |
Upcoming events: Gan & Lee Pharmaceuticals.
More events
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | ||
|---|---|---|---|---|---|---|
 | 0.26% | 0.35% | 37.46x | 3.59x | 9.51x | |
| 0.49% | 0.52% | 18.46x | 2.43x | 4.98x | |
| -.--% | -.--% | 58.06x | 7.81x | 15.36x | |
| 0.54% | 0.56% | 43.55x | 4.52x | 6.86x | |
| 2.66% | 2.89% | 22.18x | 2.77x | 4.05x | |
| -.--% | -.--% | 16.31x | 1.35x | 2.7x | |
| -.--% | -.--% | 17.11x | 3.61x | 3.38x | |
| -.--% | 0.02% | 81.97x | 7.95x | 9.81x | |
| - | - | 344.25x | 62.24x | 104.44x | |
| -.--% | -.--% | -5.03x | 1.86x | 5.65x | |
| Average | 0.44% | 0.48% | 63.43x | 9.81x | 16.67x | |
| Weighted average by Cap. | 0.65% | 0.7% | 48.29x | 6.93x | 11.86x |
Year-on-year evolution of the Yield
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Estimates Revisions
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Annual Profit -
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition